{"id":535320,"date":"2021-09-08T06:33:30","date_gmt":"2021-09-08T10:33:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/"},"modified":"2021-09-08T06:33:30","modified_gmt":"2021-09-08T10:33:30","slug":"immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/","title":{"rendered":"Immunic, Inc. to Participate in Investor and Scientific Conferences in September"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">Sept. 8, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0<b>Immunic, Inc. (Nasdaq: IMUX),\u00a0<\/b>a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in September:<\/p>\n<ul type=\"disc\">\n<li>\n          <span class=\"xn-chron\">September 13-15<\/span>: <b>H.C. Wainwright 23rd Annual Global Investment Conference. <\/b><span class=\"xn-person\">Daniel Vitt<\/span>, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at the conference. The on-demand presentation will be available for viewing beginning <span class=\"xn-chron\">September 13<\/span>, at <span class=\"xn-chron\">7:00 am ET<\/span>. An audio webcast of the presentation will be available on the &#8220;Events and Presentations&#8221; section of Immunic&#8217;s website at: <u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3281482-1&amp;h=2230753335&amp;u=http%3A%2F%2Fir.imux.com%2Fevents-and-presentations&amp;a=ir.imux.com%2Fevents-and-presentations\" rel=\"nofollow noopener\">ir.imux.com\/events-and-presentations<\/a><\/u>. An archived replay will be available on the company&#8217;s website for a period of 90 days after the conference.<br \/>\u00a0 <\/li>\n<li>\n          <span class=\"xn-chron\">September 22-25<\/span>: <b>50<sup>th<\/sup> Annual European Society for Dermatological Research (ESDR) Meeting. <\/b>Irina Betscheider, Ph.D., Clinical Operations Program Lead at Immunic, will present the first clinical experience with IMU-935, an orally available, selective inverse agonist of ROR\u03b3t. The poster presentation will be accessible on the &#8220;Events and Presentations&#8221; section of Immunic&#8217;s website at: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3281482-1&amp;h=2230753335&amp;u=http%3A%2F%2Fir.imux.com%2Fevents-and-presentations&amp;a=ir.imux.com%2Fevents-and-presentations\" rel=\"nofollow noopener\">ir.imux.com\/events-and-presentations<\/a>. <\/li>\n<ul type=\"circle\">\n<li>Poster Number: ESDR057 <\/li>\n<li>Title: <i>Safety, tolerability and pharmacokinetics of single and multiple oral doses of IMU-935 in healthy volunteers: First clinical experience with an orally available small molecule inhibitor of IL-17<br \/>\u00a0 <\/i><\/li>\n<\/ul>\n<li>\n          <span class=\"xn-chron\">September 27-30<\/span>: <b>2021<\/b><b>Cantor Virtual Global Healthcare Conference. <\/b>Dr. Vitt will participate in a fireside chat\u00a0on <span class=\"xn-chron\">Tuesday, September 28<\/span>, at <span class=\"xn-chron\">10:00 am ET<\/span>. A live audio webcast of the presentation will be available on the &#8220;Events and Presentations&#8221; section of Immunic&#8217;s website at:\u00a0<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3281482-1&amp;h=2230753335&amp;u=http%3A%2F%2Fir.imux.com%2Fevents-and-presentations&amp;a=ir.imux.com%2Fevents-and-presentations\" rel=\"nofollow noopener\">ir.imux.com\/events-and-presentations<\/a><\/u>. An archived replay will be available on the company&#8217;s website for a period of 90 days.<\/li>\n<\/ul>\n<p>\n        <b>About Immunic, Inc. <br \/><\/b>Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn&#8217;s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR\u03b3t, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr\u00e9 syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3281482-1&amp;h=2443807528&amp;u=http%3A%2F%2Fwww.imux.com%2F&amp;a=www.imux.com\" rel=\"nofollow noopener\">www.imux.com<\/a>.<\/p>\n<p>\n        <b>Cautionary Statement Regarding Forward-Looking Statements <br \/><\/b>This press release contains &#8220;forward-looking statements&#8221; that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management&#8217;s participation in investor and scientific conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management&#8217;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic&#8217;s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned &#8220;Risk Factors,&#8221; in the company&#8217;s Annual Report on Form 10-K for the fiscal year ended <span class=\"xn-chron\">December 31, 2020<\/span>, filed with the SEC on <span class=\"xn-chron\">February 26, 2021<\/span>, and in the company&#8217;s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at <a href=\"http:\/\/www.sec.gov\" rel=\"nofollow\">www.sec.gov<\/a> or ir.imux.com\/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.<\/p>\n<p>\n        <b>Contact Information<\/b>\n      <\/p>\n<p>\n        <b>Immunic, Inc.<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Jessica Breu<\/span><br \/>\n        <br \/>Head of Investor Relations and Communications<br \/>+49 89 2080 477 09<br \/><a target=\"_blank\" href=\"mailto:jessica.breu@imux.com\" rel=\"nofollow noopener\">jessica.breu@imux.com<\/a><\/p>\n<p>\n        <b>US IR Contact <br \/><\/b>Rx Communications Group <br \/><span class=\"xn-person\">Paula Schwartz<\/span><br \/>+1 917 322 2216 <br \/><u><a target=\"_blank\" href=\"mailto:immunic@rxir.com\" rel=\"nofollow noopener\">immunic@rxir.com<\/a><\/u><\/p>\n<p>\n        <b>US Media Contact <br \/><\/b>KOGS Communication <br \/><span class=\"xn-person\">Edna Kaplan<\/span><br \/>+1 781 639 1910 <br \/><u><a target=\"_blank\" href=\"mailto:kaplan@kogspr.com\" rel=\"nofollow noopener\">kaplan@kogspr.com<\/a><\/u><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder8174\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg\" title=\"Immunic, Inc. Logo (PRNewsfoto\/Immunic, Inc.)\" alt=\"Immunic, Inc. Logo (PRNewsfoto\/Immunic, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY97646&amp;sd=2021-09-08\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september-301370253.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september-301370253.html<\/a><\/p>\n<p>SOURCE  Immunic, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY97646&amp;Transmission_Id=202109080630PR_NEWS_USPR_____NY97646&amp;DateId=20210908\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK, Sept. 8, 2021 \/PRNewswire\/ &#8212;\u00a0Immunic, Inc. (Nasdaq: IMUX),\u00a0a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in September: September 13-15: H.C. Wainwright 23rd Annual Global Investment Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at the conference. The on-demand presentation will be available for viewing beginning September 13, at 7:00 am ET. An audio webcast of the presentation will be available on the &#8220;Events and Presentations&#8221; section of Immunic&#8217;s website at: ir.imux.com\/events-and-presentations. An archived replay will be available on the company&#8217;s website for a period of 90 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immunic, Inc. to Participate in Investor and Scientific Conferences in September&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535320","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunic, Inc. to Participate in Investor and Scientific Conferences in September - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunic, Inc. to Participate in Investor and Scientific Conferences in September - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Sept. 8, 2021 \/PRNewswire\/ &#8212;\u00a0Immunic, Inc. (Nasdaq: IMUX),\u00a0a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in September: September 13-15: H.C. Wainwright 23rd Annual Global Investment Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at the conference. The on-demand presentation will be available for viewing beginning September 13, at 7:00 am ET. An audio webcast of the presentation will be available on the &#8220;Events and Presentations&#8221; section of Immunic&#8217;s website at: ir.imux.com\/events-and-presentations. An archived replay will be available on the company&#8217;s website for a period of 90 &hellip; Continue reading &quot;Immunic, Inc. to Participate in Investor and Scientific Conferences in September&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T10:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunic, Inc. to Participate in Investor and Scientific Conferences in September\",\"datePublished\":\"2021-09-08T10:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/\"},\"wordCount\":849,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/\",\"name\":\"Immunic, Inc. to Participate in Investor and Scientific Conferences in September - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"datePublished\":\"2021-09-08T10:33:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunic, Inc. to Participate in Investor and Scientific Conferences in September\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunic, Inc. to Participate in Investor and Scientific Conferences in September - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/","og_locale":"en_US","og_type":"article","og_title":"Immunic, Inc. to Participate in Investor and Scientific Conferences in September - Market Newsdesk","og_description":"PR Newswire NEW YORK, Sept. 8, 2021 \/PRNewswire\/ &#8212;\u00a0Immunic, Inc. (Nasdaq: IMUX),\u00a0a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in September: September 13-15: H.C. Wainwright 23rd Annual Global Investment Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at the conference. The on-demand presentation will be available for viewing beginning September 13, at 7:00 am ET. An audio webcast of the presentation will be available on the &#8220;Events and Presentations&#8221; section of Immunic&#8217;s website at: ir.imux.com\/events-and-presentations. An archived replay will be available on the company&#8217;s website for a period of 90 &hellip; Continue reading \"Immunic, Inc. to Participate in Investor and Scientific Conferences in September\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T10:33:30+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunic, Inc. to Participate in Investor and Scientific Conferences in September","datePublished":"2021-09-08T10:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/"},"wordCount":849,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/","name":"Immunic, Inc. to Participate in Investor and Scientific Conferences in September - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","datePublished":"2021-09-08T10:33:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunic, Inc. to Participate in Investor and Scientific Conferences in September"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535320"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535320\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}